The team behind Britain’s most-used Covid booster vaccine is being sued by a German pharmaceutical firm which has accused it of stealing the technology behind the jab.
BERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus. The German-based biotech company is seeking "fair compensation" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday. When asked in a media call, Chief Executive Franz-Werner Haas did not rule out further legal action against BioNTech partner Pfizer or mRNA vaccine maker Moderna.
Issuer: CureVac / Key word(s): Legal Matter05.07.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech TÜBINGEN, Germany/ Boston, USA – July 5, 2022 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that it has moved to assert its intellectual property rights, accumulated